ML329 is primarily utilized in research settings as an inhibitor of the MITF (Microphthalmia-associated transcription factor) pathway. It is particularly significant in studies focused on melanoma, as MITF plays a crucial role in the development and progression of this type of cancer. By inhibiting MITF, ML329 helps researchers understand the molecular mechanisms underlying melanoma and explore potential therapeutic strategies. Additionally, it is used in cellular assays to investigate the role of MITF in other biological processes, such as pigment cell development and immune response modulation. Its application extends to drug discovery efforts aimed at identifying compounds that can effectively target MITF-dependent pathways in various diseases.